Print Page     Close Window     

SEC Filings

10-Q
BIOTIME INC filed this Form 10-Q on 08/09/2017
Entire Document
 

e.
It is promised to me that our identity will be kept anonymous to all the people involved in the experiment and our identity will not be published in any publication, including medical publications.
f.
The medical Institution is providing reasonable insurance to the researchers, doctors, and the medical team that are taking part in the medical experiment.
g.
In some cases, in the recommendation of the Leading Researcher and subject to the approval of the Helsinki Committee, I will get the products of the experiment without any payment, up to 3 years from the termination date of the experiment, and I will be under medical supervision during this period of time.
h.
It is promised to me, that during the process/ experiments, any question that I might have will be answered, as much as it is possible to answer it. Also, I will have the right to advice a third part/ family doctor/ family member etc. in regards of any decision that I need to make in connection of this experiment or whether I should continue to participate in it.
i.
In any case where there is a problem regarding the medical experiment, I will be able to call Professor Laufer, 02-6776424.
j.
In the event that I need to answer any questionnaire, I have the right not to answer all or part of the questions.
k.
We understand that we cannot participate in any other experiment during the term of this experiment.
l.
We understand that after signing this document we will receive a copy of it.
m.
In Medical experiments where there is a female participant (in a childbearing age), in the event of pregnancy during the experiment, the female participant will receive an advice as regarding to the health of her fetus.

4.
We declare that we received a detailed information regarding the experiment as follows:
a.
The goals of the experiment: Producing stem cells from a fetus that was created in IVF procedure (In Vitro Fertilization). Those cells can be used in research and development of new drugs and even for transplantation (to cure diabetes etc).
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
 
 
- 73 -

© Copyright BioTime, Inc.